Risk factors for non-motor symptoms in Parkinson's disease

被引:263
作者
Marinus, Johan [1 ]
Zhu, Kangdi [1 ]
Marras, Connie [2 ,3 ]
Aarsland, Dag [4 ,5 ]
van Hilten, Jacobus J. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Neurol, NL-2333ZA Leiden, Netherlands
[2] Univ Toronto, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON, Canada
[3] Univ Toronto, Edmond J Safra Program Parkinsons Res, Univ Hlth Network, Toronto, ON, Canada
[4] Kings Coll London, Dept Old Age Psychiat, Inst Psychiat Psychol & Neurosci, London, England
[5] Stavanger Univ, Ctr Age Related Med, Stavanger, Norway
关键词
IMPULSE CONTROL DISORDERS; QUALITY-OF-LIFE; MILD COGNITIVE IMPAIRMENT; EXCESSIVE DAYTIME SLEEPINESS; PSYCHIATRIC-SYMPTOMS; FOLLOW-UP; VISUAL HALLUCINATIONS; DIAGNOSTIC-CRITERIA; DEMENTIA; DEPRESSION;
D O I
10.1016/S1474-4422(18)30127-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease advances, thereby constituting a major source of disease burden for patients and caregivers. However, current understanding of NMS is incomplete, particularly as a result of the absence of standardisation of outcome definitions and the heterogeneity of the risk factors that are assessed. The best data on risk factors for NMS in Parkinson's disease come from longitudinal studies, with the strongest evidence identifying factors for cognitive impairment and dementia, hallucinations, depression, apathy, excessive daytime sleepiness, insomnia, and impulse-control disorders. Cognitive impairment, hallucinations, and depression have several common risk factors, and many other NMS share a few risk factors, showing the interdependence between NMS with advancing Parkinson's disease. Disease severity, sex, age, and antiparkinsonian medication might have roles in the development of different NMS, although only antiparkinsonian medication is potentially modifiable. Until disease-modifying therapies are developed, increased knowledge of risk factors could ameliorate early identification of patients who are at an increased risk of developing specific NMS and potentially allow improvement of symptom management or prevention of specific NMS.
引用
收藏
页码:559 / 568
页数:10
相关论文
共 93 条
  • [11] MDS research criteria for prodromal Parkinson's disease
    Berg, Daniela
    Postuma, Ronald B.
    Adler, Charles H.
    Bloem, Bastiaan R.
    Chan, Piu
    Dubois, Bruno
    Gasser, Thomas
    Goetz, Christopher G.
    Halliday, Glenda
    Joseph, Lawrence
    Lang, Anthony E.
    Liepelt-Scarfone, Inga
    Litvan, Irene
    Marek, Kenneth
    Obeso, Jose
    Oertel, Wolfgang
    Olanow, C. Warren
    Poewe, Werner
    Stern, Matthew
    Deuschl, Guenther
    [J]. MOVEMENT DISORDERS, 2015, 30 (12) : 1600 - 1609
  • [12] Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
    Biglan, Kevin M.
    Holloway, Robert G., Jr.
    McDermott, Michael P.
    Richard, Irene H.
    [J]. NEUROLOGY, 2007, 69 (02) : 187 - 195
  • [13] Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study
    Bjornestad, Anders
    Pedersen, Kenn Freddy
    Tysnes, Ole-Bjorn
    Alves, Guido
    [J]. PARKINSONISM & RELATED DISORDERS, 2017, 42 : 28 - 33
  • [14] Stages in the development of Parkinson's disease-related pathology
    Braak, H
    Ghebremedhin, E
    Rüb, U
    Bratzke, H
    Del Tredici, K
    [J]. CELL AND TISSUE RESEARCH, 2004, 318 (01) : 121 - 134
  • [15] Cognitive Change in Newly-Diagnosed Patients with Parkinson's Disease: A 5-Year Follow-up Study
    Broeders, Mark
    Velseboer, Daan C.
    de Bie, Rob
    Speelman, Johannes D.
    Muslimovic, Dino
    Post, Bart
    de Haan, Rob
    Schmand, Ben
    [J]. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2013, 19 (06) : 695 - 708
  • [16] THE PITTSBURGH SLEEP QUALITY INDEX - A NEW INSTRUMENT FOR PSYCHIATRIC PRACTICE AND RESEARCH
    BUYSSE, DJ
    REYNOLDS, CF
    MONK, TH
    BERMAN, SR
    KUPFER, DJ
    [J]. PSYCHIATRY RESEARCH, 1989, 28 (02) : 193 - 213
  • [17] Carter MJ, 2014, THER RECREAT J, V48, P275
  • [18] A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015
    Chahine, Lama M.
    Amara, Amy W.
    Videnovic, Aleksandar
    [J]. SLEEP MEDICINE REVIEWS, 2017, 35 : 33 - 50
  • [19] International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
    Chaudhuri, Kallol Ray
    Martinez-Martin, Pablo
    Schapira, Anthony H. V.
    Stocchi, Fabrizio
    Sethi, Kapil
    Odin, Per
    Brown, Richard G.
    Koller, William
    Barone, Paolo
    MacPhee, Graeme
    Kelly, Linda
    Rabey, Martin
    MacMahon, Doug
    Thomas, Sue
    Ondo, William
    Rye, David
    Forbes, Alison
    Tluk, Susanne
    Dhawan, Vandana
    Bowron, Annette
    Williams, Adrian J.
    Olanow, Charles W.
    [J]. MOVEMENT DISORDERS, 2006, 21 (07) : 916 - 923
  • [20] The Parkinson's disease sleep scale:: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease
    Chaudhuri, KR
    Pal, S
    DiMarco, A
    Whately-Smith, C
    Bridgman, K
    Mathew, R
    Pezzela, FR
    Forbes, A
    Högl, B
    Trenkwalder, C
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (06) : 629 - 635